Jounce Therapeutics to Announce Second Quarter 2018 Financial Results and Host Conference Call on Thursday, August 9, 2018
02 août 2018 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Presents Preliminary Efficacy Data from Ongoing Phase 1/2 ICONIC Trial of JTX-2011 in Patients with Advanced Cancers
02 juin 2018 16h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., June 02, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Present Data from Ongoing ICONIC Trial of JTX-2011 at the 2018 American Society of Clinical Oncology Annual Meeting
16 mai 2018 17h01 HE
|
Jounce Therapeutics, Inc.
ICONIC Target Enrollment Met Across Four Combination Cohorts Company to Host Investor Event and Live Webcast on Monday, June 4 CAMBRIDGE, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- Jounce...
Jounce Therapeutics Reports First Quarter 2018 Financial Results
09 mai 2018 06h30 HE
|
Jounce Therapeutics, Inc.
- Preliminary efficacy data from Phase 1/2 ICONIC trial to be presented as an oral presentation at the 2018 ASCO Annual Meeting - - Company to host conference call and webcast today at 8:00 AM ET - ...
Jounce Therapeutics to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018
02 mai 2018 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., May 02, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Present at Deutsche Bank 43rd Annual Health Care Conference
01 mai 2018 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., May 01, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Present Nonclinical Translational Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting
12 avr. 2018 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., April 12, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
08 mars 2018 06h30 HE
|
Jounce Therapeutics, Inc.
- Remain on track to announce preliminary efficacy data for the Phase 1/2 ICONIC trial in the second quarter of 2018 - - Reiterate 2018 strategy to advance clinical and research pipeline to drive...
Jounce Therapeutics to Present at Cowen and Company 38th Annual Health Care Conference
05 mars 2018 08h00 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Thursday, March 8, 2018
01 mars 2018 16h52 HE
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., March 01, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...